ClinicalTrials.gg
RecruitingNCT07225543Updated May 22, 2026

2-HOBA in Systemic Lupus Erythematosus

A Phase 2 interventional study of 2-HOBA acetate (2-Hydroxybenzlamine acetate) and Placebo in Systemic Lupus Erthematosus (SLE), sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Vanderbilt University Medical Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Planned enrollment
252nd of 407
42 · median 70
Started
2026
with 28 others
Phase 2
120 of 477
10 open now
Primary completion
2030-07
later than 109 of 125 live
Registered
459th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 252nd largest by planned enrollment of the 407 interventional ones that give a count, is one of 29 that started in 2026, is one of 120 in phase 2, reaches primary completion later than 109 of the 125 other live ones, and was the 459th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

81 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

This is a phase II randomized, placebo-controlled, double-blind, cross-over study to determine the effect of isolevuglandin (IsoLG) scavenging by 2-HOBA on blood pressure and immune activation in patients with SLE. 42 patients with stable SLE will be randomized to treatment sequence to receive placebo or 500mg 2-HOBA three times a day for 8 weeks followed by a 4 week washout and then 8 weeks of the other agent.

Primary outcome measures include change in 24-hour blood pressure and NETosis. This study will provide mechanistic information on the role of IsoLGs in autoimmune disease-associated hypertension and immune activation.

Read the detailed description

Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease with a markedly increased prevalence of not only hypertension but also resistant hypertension. Hypertension, along with other factors, leads to a 2 to 3-fold increase in risk of cardiovascular disease in SLE. Other than glucocorticoids and immunosuppression, there are few therapeutic options for patients with SLE and none that are known to have a beneficial effect on hypertension and cardiovascular disease; in fact, glucocorticoids have substantial deleterious effects. The increased prevalence of hypertension and its greater severity in SLE patients are unexplained; however, work from our group and others increasingly implicates activation of the immune system in the pathogenesis of hypertension. Moreover, our data suggest that downstream products of oxidative stress, specifically isolevuglandins (IsoLGs), drive immune activation and hypertension.

IsoLGs are highly reactive dicarbonyl products of oxidative stress that bind covalently to proteins causing conformational changes rendering them immunogenic and proinflammatory. Two decades of work at Vanderbilt led to the identification of 2-hydroxybenzylamine (2-HOBA) as a highly effective scavenger of reactive dicarbonyls such as IsoLGs. Scavenging reactive dicarbonyls is preferable to using antioxidants because reactive oxygen species are necessary for normal cellular function. In animal models of SLE, hypertension, and atherosclerosis 2-HOBA reduced inflammation, neutrophil extracellular traps (NETosis), blood pressure, and atherosclerosis, and in human phase I clinical studies with healthy volunteers it was well tolerated.

This is a mechanistic, proof-of-concept phase II study with a randomized, placebo-controlled, double-blind, cross-over design to determine the effect of IsoLG scavenging by 2-HOBA on blood pressure and immune activation in patients with SLE. 42 patients with stable SLE will be randomized to treatment sequence to receive placebo or 500mg 2-HOBA three times a day for 8 weeks followed by a 4 week washout and then 8 weeks of the other agent. Comparing 2-HOBA and placebo arms, primary outcomes include change in 24-hour blood pressure and immune activation measured by NETosis.

03

Conditions studied

  • Systemic Lupus Erthematosus (SLE)

Keywords

  • systemic lupus erythematosus
  • SLE
  • lupus
  • oxidative stress
  • hypertension
  • blood pressure
  • NETosis
  • isolevuglandins
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Age ≥18 years
  • Female (biological)
  • Meeting the 2019 European League Against Rheumatism/ American College of Rheumatology classification criteria for SLE32
  • No change in ≥3 months
  • Stable prednisone (or equivalent) dose ≤ 20mg/ day for ≥ 1 month
  • Elevated blood pressure defined as >120 and \< or = 160 mmHg systolic or >80 and \< or = 110 mmHg diastolic blood pressure at screening visit
  • No change in anti-hypertensive dose ≥2 weeks
  • Willingness to stop NSAIDs for ≥2 weeks before and throughout the study
  • If of , willingness to use effective throughout the study and 4 weeks after completion of the study (examples: condom, diaphragm, oral contraceptive pill, intrauterine device)

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Male (biological)
  • Active cancer except for non-melanoma skin cancer
  • Prior diagnosis of liver cirrhosis or the following abnormal liver function studies: or ALT >1.5x the or total ≥1.5 mg/dl
  • Active infection requiring medical intervention
  • Major surgery in ≤ 3 months
  • Aspirin allergy
  • Use of MAO-I
  • Estimated \<30 ml/min
  • Known atrial fibrillation
  • Severe comorbid condition
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Placebo First

    Placebo for first 8 weeks, then washout for 4 weeks, and then 2-HOBA acetate for 8 weeks

    Drug: 2-HOBA acetate (2-Hydroxybenzlamine acetate) · Drug: Placebo

  • Experimental
    2-HOBA First

    2-HOBA acetate for first 8 weeks, then washout for 4 weeks, and then placebo for 8 weeks

    Drug: 2-HOBA acetate (2-Hydroxybenzlamine acetate) · Drug: Placebo

Interventions

  • Drug2-(AMINOMETHYL)PHENOLStudies of 2-(AMINOMETHYL)PHENOL2-(AMINOMETHYL)PHENOL pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2-HOBA acetate (2-Hydroxybenzlamine acetate) 500mg (provided as two 250mg capsules) three times per day

    Also known as: 2-hydroxybenzylamine, 2-HOBA, salicylamine, IUPAC name: 2-(aminomethyl)phenol

  • DrugPlacebo

    Placebo (provided as two capsules) three times per day

    Also known as: indentical placebo

06

What researchers measure

Primary outcomes

  1. 24-hour systolic blood pressure

    Investigators will measure change in 24-hour systolic blood pressure

    Time frame: Measured at the beginning and end of each phase at weeks 0, 8, 12, and 20.

  2. NETosis

    Investigators will measure change in NETosis by ELISA assessing circulating NET concentration

    Time frame: Measured at beginning and end of each phase at weeks 0, 8, 12, and 20.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The following data files will be produced: Demographic/ clinical data such as age, race, sex, SLE disease activity measures, and medication use Standard clinical laboratory measurements such as complete blood count, complete metabolic panel, complement C3 and C4, dsDNA antibody titer, erythrocyte sedimentation rate, urinalysis, spot urine protein and creatinine. 24-hour blood pressure measurements NETosis data type 1 interferon signature Identifiable data will be de-identified and anonymized prior to sharing. Given the rarity of the disease, small geographic area of recruitment, and very specific manifestations of SLE in individual patients, the risk of re-identification of participants is real. Thus, to ensure privacy concordant with the requirements of the institutional review board, information on specific SLE manifestations will not be shared and demographic variables with few participants may be collapsed/ aggregated (e.g. age, race) to anonymize data.

Supporting information: Study protocol

Time frame: Data will be made available upon publication of study results or end of the performance period, whichever comes first. The data shared will be archived and available on the Vivli platform for request by researchers for a minimum of 10 years after contribution.

Access criteria: The Vivli platform has multiple levels of protection for managing human participant data. Each user must sign a Data Use Agreement and there is an established policy for managing violations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jul 2030, 50 months after the start.

Of 95 phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 55. This study's planned 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2025
First posted
Nov 6, 2025
StartActual
May 15, 2026
Primary completionEst.
Jul 31, 2030
CompletionEst.
Jul 31, 2030
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07225543
Responsible party
Michelle Ormseth (Associate Professor, Vanderbilt University Medical Center) — Principal investigator
First posted
Nov 6, 2025
Start date
May 15, 2026
Primary completion
Jul 31, 2030 (estimated)
Completion
Jul 31, 2030 (estimated)
Last update
May 22, 2026

Study contacts

Phicharmon Kulapatana (study coordinator)
Contact
phicharmon.kulapatana@vumc.org
615-936-5747
Michelle J Ormseth, MD, MSCI
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 2-(AMINOMETHYL)PHENOL

Start the discussion